Description: Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
Home Page: www.staidson.com
No. 36, Jinghai Er Road
Beijing,
100176
China
Phone:
86 10 6751 9888
Officers
| Name | Title |
|---|---|
| Mr. Zhi Wen Zhou | Chairman & Sec. |
| Mr. Wang Chao | Gen. Mang. |
| Mr. Shicheng Li | Financial Controller |
Exchange: SHE
Country: CN
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.7125 |
| Price-to-Sales TTM: | 14.2986 |
| IPO Date: | 2011-04-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 873 |